Principal components of serum biomarkers
| PC1 | PC2 | PC3 | |
| Variance explained | 43% | 10% | 6% |
| Contributing biomarkers | EPHB4 | TIMP4 | NT-proBNP |
| TR-AP | IL-1RT2 | ST2 | |
| TNF-R2 | COL1A1 | PRTN3 | |
| TNF-R1 | GP6 | MB | |
| U-PAR | SELP | PON3 | |
| Subcellular localisation | – | Integrin αIIb–β3 complex | Troponin complex Striated muscle thin filament Myofilament Extracellular region |
| Biological process | Negative regulation of extracellular matrix constituent secretion Positive regulation of apoptotic process involved in morphogenesis Pulmonary valve development Negative regulation of cardiac muscle hypertrophy Aortic valve development | – | – |
| Clinical associations | PC1 differentiates between patients undergoing ToF repair versus PVR (2.3±5.4 vs −4.3±5.7, p≤0.001) | PC2 differentiates between patients before versus after ToF repair (−2.7±2.1 vs 1.2±2.7, p<0.001) | PC3 is increased at the early postoperative time point, compared with other time points (3.2±2.7 vs −0.7±1.7, p<0.001) |
| PC2 correlates with haematocrit for patients before ToF repair (r=0.56, p=0.006) |
COL1A1, collagen alpha-1(I) chain; EPHB4, ephrin type-B receptor 4; GP6, platelet glycoprotein VI; IL-1RT2, interleukin-1 receptor type 2; MB, myoglobin; NT-proBNP, N-terminal pro-brain natriuretic peptide; PC, principal component; PON3, paraoxonase-3; PRTN3, myeloblastin; PVR, pulmonary valve replacement; SELP, P-selectin; ST2, suppression of tumorigenicity-2; TIMP4, metalloproteinase inhibitor 4; TNF-R, tumour necrosis factor receptor; ToF, tetralogy of Fallot; TR-AP, tartrate-resistant acid phosphatase type 5; U-PAR, urokinase receptor.